

***Fiscal Year 2024 (FY24) Department of Defense Peer Reviewed Cancer Research Program (PRCRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Advancing Cancer Care Through Clinical Trials Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRCRPACCCTA</p>	<p>Principal Investigator (PI): Independent investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Preproposal required; application submission is by <i>invitation only</i>. • Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer. • Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials to determine efficacy in relevant patient populations. • Must address at least one of the FY24 PRCRP Topic Areas. • Must address at least one of the FY24 PRCRP Military Health Focus Areas. • Must address at least one of the FY24 PRCRP Overarching Challenges. • Preliminary data are required. • Investigational New Drug/Investigational Device Exemption application required by application submission deadline. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$3 million (M) for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): July 24, 2024 5:00 p.m. Eastern Time (ET)</p> <p>Application: October 15, 2024 11:59 p.m. ET</p>
<p>Career Development Award –Scholar Option</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRCRPCDA-SO</p>	<p>Principal Investigator (PI): Independent investigators at or above the level of Assistant Professor or Instructor (or equivalent) on tenure track and within 7 years after completion of their terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.</p>	<ul style="list-style-type: none"> • Letter of Intent is required. An invitation to submit a full application is <i>not</i> required. • Supports the addition of new early-career investigators (Scholars) to the unique, interactive PRCRP Virtual Cancer Center focused on fostering the next generation of cancer researchers. • The Scholars will be required to interact within the virtual cancer center and with the Virtual Cancer Center Director and Deputy Director. • The Scholar Option provides intensive mentoring, national networking, and peer group for junior faculty. • A Career Guide – an experienced cancer researcher with cancer funding – is required. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$800,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): July 12, 2024 5:00 p.m. ET</p> <p>Application: July 26, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
	<p>Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research.</p>	<ul style="list-style-type: none"> The Career Guide is not required to be at the same institution as the Scholar. Must address at least one of the FY24 PRCRP Topic Areas. Must address at least one of the FY24 PRCRP Military Health Focus Areas. Must address at least one of the FY24 PRCRP Overarching Challenges. Preliminary data are not required. Clinical trials are not allowed. 		
<p>Convergent Science Cancer Consortium Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRCRPSCCA</p>	<p>Coordinating Center (Initiating PI): Investigators at or above the level of Associate Professor (or equivalent).</p> <p>Partnering PIs for the Research Sites, only: Investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> Preproposal required; application submission is by <i>invitation only</i>. Supports a transdisciplinary collaboration of scientists, clinicians, and patient advocates working to illuminate and address urgent and complex issues of importance in cancer research. The proposed consortium will be comprised of a Coordinating Center that both supports the infrastructure of the consortium and serves as a Research Site, and two additional Research Sites. Must address at least three of the FY24 PRCRP Topic Areas. Must address at least one of the FY24 PRCRP Military Health Focus Areas. Must address at least one of the FY24 PRCRP Overarching Challenges. Clinical trials are allowed. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$20M for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): July 24, 2024 5:00 p.m. Eastern Time (ET)</p> <p>Application: October 15, 2024 11:59 p.m. ET</p>
<p>Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRCRPIA</p>	<p>Independent investigator with a faculty-level appointment (or equivalent).</p> <p>Each investigator may be named as the PI on only one FY24 Idea Award application. Investigators may be named as a collaborator on more than one application.</p>	<ul style="list-style-type: none"> Preproposal required; application submission is by <i>invitation only</i>. Supports innovative <i>basic research</i> that may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities. Emphasis on innovation. Must address at least one of the FY24 PRCRP Topic Areas. Must address at least one of the FY24 PRCRP Military Health Focus Areas. 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$400,000 for direct costs. Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): June 21, 2024 5:00 p.m. ET</p> <p>Application: September 26, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> • Must address at least one of the FY24 PRCRP Overarching Challenges. • Preliminary data are not required. • Clinical trials are not allowed. 		
<p>Impact Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRCRPIPA</p>	<p>Independent investigators at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> • Preproposal required; application submission is by invitation only. • Supports hypothesis-driven, high-impact research. • Supports mature research projects that specifically focus on critical scientific or clinical cancer issues and have the potential to make a major near-term impact. • Must address at least one of the FY24 PRCRP Topic Areas. • Must address at least one of the FY24 PRCRP Military Health Focus Areas. • Must address at least one of the FY24 PRCRP Overarching Challenges. • Preliminary data are required. • Clinical trials are allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1M for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 21, 2024 5:00 p.m. ET</p> <p>Application: September 26, 2024 11:59 p.m. ET</p>
<p>Patient Well-Being and Survivorship Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRCRPPWSA</p>	<p>Independent investigator with a faculty-level appointment (or equivalent).</p>	<ul style="list-style-type: none"> • Letter of Intent is required. An invitation to submit a full application is not required. • Supports innovative research studies to advance studies in preservation of function (physical ability), quality of life, symptom management, resilience, relief from neurocognitive deficits, and support for psychosocial issues related to cancer diagnosis, treatment, and survivorship. • Must address at least one of the FY24 PRCRP Topic Areas. • Must address at least one of the FY24 PRCRP Military Health Focus Areas. • Must address at least one of the FY24 PRCRP Overarching Challenges. • Preliminary data are required. • Pilot clinical trials are allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1M for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): July 12, 2024 5:00 p.m. ET</p> <p>Application: July 26, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Virtual Cancer Center Director Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT942524PRCRPVCCDA</p>	<p>Director (Initiating PI): Investigators at or above the level of Associate Professor (or equivalent).</p> <p>Deputy Director (Partnering PI): Investigators at or above the level of Associate Professor (or equivalent); Deputy Director must be at a different institution and must be in a different cancer discipline than the Director.</p>	<ul style="list-style-type: none"> • Preproposal required; application submission is by <i>invitation only</i>. • Supports the Director and Deputy Director of a unique, interactive virtual cancer center (VCC) focused on bringing together early career investigators (Scholars) and their mentors (Career Guides) to interrogate the commonalities of cancer. • The VCC Leadership must demonstrate a strong record of mentoring and training early career investigators, a commitment to leadership, and the ability to objectively assess the progress of all of the Scholars in the VCC. • Early-career investigators interested in applying to the Virtual Cancer Center should refer to the Career Development Award – Scholar Option Program Announcement (HT942524PRCRPCDASO). • Must address at least one of the FY24 PRCRP Military Health Focus Areas. • Must address at least three different FY24 PRCRP Topic Areas. • Must address at one of the FY24 PRCRP Overarching Challenges. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.75M for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): July 24, 2024 5:00 p.m. Eastern Time (ET)</p> <p>Application: October 15, 2024 11:59 p.m. ET</p>